# Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)

> **NCT00996944** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 34 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** Ropinirole immediate release (IR)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00996944
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11-30
- **Primary completion:** 2010-06-01
- **Final completion:** 2010-06-29
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Because GSK concluded that it was impossible to recruit sufficient participants within a reasonable timeframe.
- **Last updated:** 2018-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00996944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00996944, "Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00996944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*